The Balochistan Liberation Army (BLA), a banned separatist militant group, has escalated tensions in Pakistan's restive Balochistan province by releasing a harrowing new video showing seven captured ...

The Baloch Liberation Army (BLA) reportedly released a video purportedly showing Pakistani Army personnel in its custody, as a self-declared deadline for a proposed prisoner exchange continues to ...

The Baloch Liberation Army (BLA) has released a video purportedly showing captured Pakistani soldiers pleading for help, alleging that they have been abandoned by the army amid a self-declared ...

Tom Neuwirth, also known as Conchita Wurst, and Johannes Pietsch, also known as JJ, are launching a joint podcast on FM4. Starting February 22, 2026, they will discuss weekly under the title “Bussi ...

A Prescription Drug User Fee Act target date of December 19, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

The Balochistan Liberation Army (BLA) has released a disturbing video allegedly showing captured Pakistani soldiers pleading for help, intensifying pressure on Islamabad amid rising regional tensions.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority ...

NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the ...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today ...

The deadline will reportedly expire on February 22. The separatist militant group, the Baloch Liberation Army (BLA), has claimed it has captured several Pakistani security forces personnel, ...

Dr Reddy’s Laboratories announced that the US Food and Drug Administration (FDA) has accepted for review, its 351 (k) Biologics License Application (BLA) IV for infusion formulation for DRL_AB, a ...

Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) BLA is ...